ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08905
-0,04%
Bitcoin
67.206,51
0,40%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Outlook Therapeutics Inc (OTLK)

  7. Outlook Therapeutics Inc (OTLK) News

OTLK

Outlook Therapeutics (OTLK)

Outlook Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OTLK
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202423h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
15/05/202423h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
15/05/202423h00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
13/05/202414h50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
09/05/202414h45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKOutlook Therapeutics Inc
07/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OTLKOutlook Therapeutics Inc
06/05/202422h09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OTLKOutlook Therapeutics Inc
02/05/202415h05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKOutlook Therapeutics Inc
29/04/202415h00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKOutlook Therapeutics Inc
15/04/202422h15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKOutlook Therapeutics Inc
22/03/202412h35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKOutlook Therapeutics Inc
18/03/202422h10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKOutlook Therapeutics Inc
12/03/202413h05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKOutlook Therapeutics Inc
11/03/202421h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
08/03/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OTLKOutlook Therapeutics Inc
07/03/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202423h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OTLKOutlook Therapeutics Inc
14/02/202422h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
14/02/202414h05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202413h00Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:OTLKOutlook Therapeutics Inc
08/02/202412h59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
31/01/202422h01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
31/01/202414h05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKOutlook Therapeutics Inc
29/01/202423h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OTLKOutlook Therapeutics Inc
24/01/202423h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:OTLKOutlook Therapeutics Inc
24/01/202412h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OTLKOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLK

Kürzlich von Ihnen besucht

NASDAQ
MEOAU
Minority Equality Opport...
UNSW
LTTETH
COIN
TOKKKUST
TOK
LSE
51XT
Sigma Fin
USOTC
GRNH
GreenGro Technologies (CE)
BIT
F16893
Vontobel Financial Produ...
ASX
GXNDC
LSE
0LDA
Tata Motors
ASX
PF1
Pathfinder Resources
BIT
F18892
Vontobel Financial Produ...
USOTC
MKHVS
370 Markets (CE)
NASDAQ
PAET
USOTC
HKTTF
Hkt Trust and Hkt (PK)
EU
IEWRD
BNP ETF EWRD iNav
ASX
WHCN
NYSE
TDA
Telephone and Data Systems
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten